This section highlights FDA-related milestones and regulatory updates for drugs developed by Iovance Biotherapeutics (IOVA).
Over the past two years, Iovance Biotherapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
IOV-5001 and Lifileucel. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
IOV-5001 FDA Regulatory Events
IOV-5001 is a drug developed by Iovance Biotherapeutics for the following indication: next-generation interleukin-12 (IL-12) tethered TIL therapy.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IOV-5001
- Announced Date:
- June 1, 2026
- Indication:
- next-generation interleukin-12 (IL-12) tethered TIL therapy.
Announcement
Iovance Biotherapeutics announced allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy.
AI Summary
Iovance Biotherapeutics said the U.S. Food and Drug Administration has allowed it to move ahead with an investigational new drug application for a Phase 1/2 basket trial of IOV-5001, a next-generation IL-12 tethered TIL therapy. The study is expected to start enrolling in the second half of 2026 and will test one-time treatment without using IL-2.
The trial will include patients with advanced colorectal cancer, triple-negative breast cancer, estrogen receptor-low breast cancer, and other common solid tumors that cause more than 100,000 U.S. deaths each year. IOV-5001 is designed to make IL-12 only inside tumors and keep it attached to the cell surface, which may improve safety by limiting release into the bloodstream. The therapy is also built to support higher cell doses and may improve on earlier TIL treatments in hard-to-treat, “cold” tumors.
Read Announcement
Lifileucel FDA Regulatory Events
Lifileucel is a drug developed by Iovance Biotherapeutics for the following indication: For the Treatment of Advanced Melanoma.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Lifileucel
- Announced Date:
- February 5, 2026
- Indication:
- For the Treatment of Advanced Melanoma
Announcement
Iovance Biotherapeutics, announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma.
AI Summary
Iovance Biotherapeutics reported real-world, retrospective clinical data showing commercial Amtagvi® (lifileucel) has a best-in-class profile with unprecedented response rates in patients with advanced, unresectable or metastatic melanoma. These real-world results were highlighted in an oral presentation at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) in Salt Lake City, Utah.
Daniel Kirby, Iovance’s Chief Commercial Officer, said the data show impressive response rates plus unprecedented five-year durability and survival. He noted patients treated earlier had better outcomes. The findings suggest Amtagvi may offer durable benefit in routine clinical practice for people whose melanoma has progressed after prior therapies. Further study and follow-up will clarify how these real-world results fit into treatment decisions.
Read Announcement- Drug:
- Lifileucel
- Announced Date:
- August 18, 2025
- Indication:
- For the Treatment of Advanced Melanoma
Announcement
Iovance Biotherapeutics, announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy.
AI Summary
Iovance Biotherapeutics announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a T cell therapy. It is approved for adult patients with unresectable or metastatic melanoma after at least one prior systemic therapy, including a PD-1 blocking antibody and, if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.
Frederick Vogt, Interim CEO of Iovance, said this marks the company’s first marketing authorization outside the U.S. He noted that Iovance plans to open its first Canadian treatment center soon and is moving ahead with its strategy in other markets.
The conditional approval was based on safety and efficacy data from the global, multicenter C-144-01 Phase 2 trial. In that study, patients previously treated with anti-PD-1 therapy and targeted agents showed measurable tumor responses and lasting benefits. Final confirmation of clinical benefit will depend on results from ongoing trials.
Read Announcement
